Do GH peptides like MK-677 and CJC-1295 actually build muscle?

The short answer

Growth-hormone peptides — CJC-1295, ipamorelin, MK-677, sermorelin — are the compounds most often sold for muscle, on the logic that they raise GH and IGF-1. The honest evidence says they produce modest, partly-water body-composition changes with inconsistent strength gains, not the size-and-power effect the marketing implies.

Evidence tier: This is Tier 2–3. The GH/IGF-1 axis and these compounds' effect on it is well-established (Tier 2); the claim that they meaningfully build functional muscle in healthy, trained adults is weak and partly extrapolated (Tier 3).

The essentials:

• They raise IGF-1 — that part is real and measurable.
• Body-composition gains are modest and partly water, not all contractile muscle.
• Strength effects are inconsistent across the available data.
• They're a recovery/body-comp adjunct, not an anabolic engine.

This is part of our muscle vertical; see the muscle and recomposition cornerstone and the GH secretagogue cycling article.

The mechanism — and why it oversells

Evidence tier: 2 — GH/IGF-1 pharmacology.

The pitch is mechanistically seductive: GH secretagogues prompt your pituitary to release more growth hormone, which raises IGF-1, and IGF-1 is a genuinely anabolic hormone involved in muscle growth. CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist) stimulate the GH-release pathway; MK-677 does the same orally and continuously (Teichman 2006). So on paper, more GH and IGF-1 should mean more muscle.

The reason it oversells is that raising a hormone within or near the physiological range doesn't reproduce the effect of the supraphysiological androgen levels that actually transform physiques. GH and IGF-1 support tissue maintenance, recovery, and some lean-mass change, but in healthy adults the muscle-and-strength payoff is far smaller than the mechanism suggests — and a good chunk of the early "gain" is water and glycogen-associated weight, not new contractile tissue. The gap between "raises an anabolic hormone" and "builds usable muscle" is exactly where the marketing lives.

What the body-composition data actually shows

Evidence tier: 2–3 — clinical body-composition studies.

The most informative data comes from MK-677, which has been studied more rigorously than the injectables. In healthy older adults, MK-677 reliably raised IGF-1 and increased fat-free mass on the scale — but the increase was substantially water, and the studies did not demonstrate the clean strength-and-function improvements people imagine (Nass 2008). Reviews of GH secretagogues as a class reach a similar conclusion: measurable hormonal and body-composition effects, but modest and not equivalent to anabolic agents for muscle and strength (Sigalos 2018).

For the injectable secretagogues (CJC-1295, ipamorelin, sermorelin), rigorous body-composition data in healthy trained adults is even thinner — much of the enthusiasm is mechanistic and anecdotal rather than trial-backed. The fair summary is that these compounds do what they say to the hormone (raise GH/IGF-1) but the downstream muscle effect is small, partly water, and inconsistent on strength. That's a meaningful distinction for anyone deciding whether the cost, injections, and gray-market risk are worth it for a muscle goal specifically.

Is the weight gain muscle or water?

Evidence tier: 2–3 — interpreting body-composition readouts.

This question matters more than people realize, because the scale and even DXA "lean mass" readings can mislead. GH and GH secretagogues cause fluid retention, and that water shows up as weight and as "fat-free mass," which is easy to misread as muscle. The early, often-cited "gains" on MK-677 — feeling fuller, the scale moving up quickly — are substantially this water effect, which is why they appear fast (real muscle doesn't accrue in days) and why they can vanish when the compound is stopped.

The practical implication is to be skeptical of rapid weight gain on a GH peptide as evidence of muscle. Real muscle accrues slowly and tracks with strength; water-driven weight appears quickly and doesn't. If someone gains several pounds in two weeks on MK-677, that's overwhelmingly water, not new tissue. Judging these compounds by the scale flatters them; judging them by strength and by what remains after the water normalizes gives a more honest — and more deflating — picture. The fuller, "more pumped" look some people like is real and may be worth something cosmetically, but it isn't muscle.

So is there any muscle use for them?

Evidence tier: 3 — narrow, adjunct role.

There's a defensible but narrow case. As a recovery and sleep adjunct, GH secretagogues — especially around-sleep dosing that respects GH's natural nocturnal pulse — may support the recovery side of training, which has a second-order benefit for muscle by keeping you training well. As a modest body-composition tool, they may produce a small lean-mass nudge alongside the water. And in genuine clinical GH-axis deficiency (a medical diagnosis, not a biohacking guess), GH-axis therapy has real indications. None of those is "they build muscle like a steroid."

The disciplined position for a muscle goal is therefore to keep GH peptides in the recovery/optimization category, not the anabolic one, and to weigh the real costs — water retention, increased appetite, effects on insulin sensitivity and blood sugar (especially MK-677), desensitization with continuous use, cost, injections, and gray-market sourcing — against a modest, partly-water benefit. For most people chasing muscle, that math favors putting the effort into training, protein, and sleep, with a GH peptide as an optional, clear-eyed add-on rather than the centerpiece. The cycling and side-effect detail is in our GH secretagogue cycling article; the GLP-1-specific muscle context is in muscle loss on GLP-1s.

Comparing the GH peptides for a muscle goal

Evidence tier: 2–3 — comparative pharmacology.

If someone decides to use a GH peptide despite the modest case, the options differ in ways worth understanding. Ipamorelin is a selective ghrelin-receptor agonist that produces a clean, short GH pulse with minimal effect on cortisol or prolactin, which is why it's favored for a more physiological, pulse-respecting approach — but on its own its effect is mild. CJC-1295 is a GHRH analog often paired with ipamorelin (the classic CJC-1295 + ipamorelin stack) to hit two levers of GH release at once; the long-acting "DAC" version sustains elevation, which trades a more continuous effect for more desensitization pressure. Sermorelin is a shorter-acting GHRH analog, gentler and closer to the natural pulse but correspondingly modest. MK-677 is the outlier: oral, convenient, and continuously active, which is exactly why it produces the most visible scale change — and the most water retention, appetite increase, and metabolic considerations.

One genuinely useful practice across all of them is to track IGF-1 on bloodwork rather than judging by feel, since IGF-1 is the measurable downstream marker of whether the compound is doing what it claims to the hormone. A rising IGF-1 confirms the pathway is responding; a flat one despite a steady dose suggests either desensitization or a sourcing problem. That objective readout is worth far more than the subjective "fuller" sensation, which is largely the water effect and tells you little about muscle.

For a muscle goal specifically, none of these distinctions changes the core conclusion — the body-composition effect is modest and partly water across the board. The selective, pulse-respecting options (ipamorelin, sermorelin, pulsatile CJC) are the more physiologically sensible if you use one, while MK-677's continuous stimulation buys convenience and visible fullness at the cost of more side effects and faster desensitization. The choice is really about recovery and tolerability preferences, not about which one "builds more muscle," because for muscle the honest answer is that they're all minor. Our CJC-1295/ipamorelin stack guide covers the most common pairing in detail.

Limitations

This is an educational guide, not medical advice or a protocol.

• GH secretagogues raise IGF-1 but muscle-and-strength effects are modest and inconsistent.
• Much early body-comp gain is water, not contractile muscle, and can reverse on stopping.
• Injectable-secretagogue muscle data in healthy adults is thin — largely mechanistic and anecdotal.
• MK-677 carries metabolic considerations — water retention, appetite, insulin sensitivity.
• Clinical GH deficiency is a medical diagnosis, not a self-assessed reason to use these.
• Gray-market sourcing carries real risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

GH peptides do raise IGF-1 — that part is real — but the muscle payoff is modest, partly water, and inconsistent on strength, not the size-and-power transformation the marketing implies. Much of the fast early "gain," especially on MK-677, is fluid that reverses when you stop. The defensible uses are as a recovery and sleep adjunct, a small body-composition nudge, or genuine clinical GH-axis therapy — none of which is a steroid-like anabolic effect. Weighed against the side effects, cost, and sourcing risk, GH peptides are a clear-eyed optional add-on for a muscle goal, not the engine.

The honest mental model is to separate "raises an anabolic hormone" from "builds usable muscle," because GH peptides do the first far more reliably than the second. The people who benefit treat them as recovery and optimization tools layered on excellent training and nutrition, judge them by strength rather than the scale, and stay aware that the quick weight is water. The people who are disappointed expect needle-driven muscle and get a fuller-looking but not meaningfully stronger physique for their money and risk. Set the expectation at the modest, partly-water reality, and you can decide clearly whether these compounds are worth it for you — which, for a pure muscle goal, they often aren't.

Related on this site

• Peptides for muscle and recomposition (cornerstone)
• Muscle loss on GLP-1s: how to prevent it
• Preserving lean mass while cutting
• GH secretagogue cycling and desensitization
• Peptides and resistance training: recovery synergy
• Growth Hormone pillar
• Our evidence-tier framework
• Finnrick vendor testing

References

• Teichman SL, Neale A, Lawrence B, et al. 2006. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 91(3):799-805. PMID 16352683 — CJC-1295 GH/IGF-1 stimulation.
• Nass R, Pezzoli SS, Oliveri MC, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 149(9):601-611. PMID 19011247 — MK-677 raises IGF-1 and fat-free mass (water-inclusive).
• Sigalos JT, Pastuszak AW. 2018. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 6(1):45-53. PMID 28330835 — GH-secretagogue class review.
• Murphy MG, Plunkett LM, Gertz BJ, et al. 1998. MK-677, an orally active growth hormone secretagogue. J Clin Endocrinol Metab. 83(2):320-325. PMID 9467536 — MK-677 pharmacology and sustained stimulation.